Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26209577 | 0.89 | KDM1A (0.39) | FPR2KDM1AFGFR2FGFR1PDE4A | |
| SCHEMBL17827784 | 0.89 | KDM1A (0.39) | FPR2KDM1AFGFR2FGFR1PDE4A | |
| SCHEMBL28559153 | 0.88 | ESR2 (0.41) | FPR2KDM1AFGFR2FGFR1FFAR4 | |
| SCHEMBL10052063 | 0.88 | ESR2 (0.41) | FPR2KDM1AFGFR2FGFR1FFAR4 | |
| SCHEMBL16769036 | 0.88 | KDM1A (0.40) | FPR2KDM1AFGFR2FGFR1ALOX5AP | |
| SCHEMBL16769035 | 0.88 | CYP3A4 (0.41) | FPR2KDM1AFGFR2FGFR1ALOX5AP | |
| SCHEMBL4402648 | 0.87 | KDM1A (0.37) | FPR2KDM1AFGFR2FGFR1FFAR4 | |
| SCHEMBL21567656 | 0.87 | KDM1A (0.37) | FPR2KDM1AFGFR2FGFR1FFAR4 | |
| SCHEMBL15256178 | 0.87 | ESR2 (0.40) | FPR2KDM1AFGFR2FGFR1FFAR4 | |
| SCHEMBL17715213 | 0.87 | KDM1A (0.37) | FPR2KDM1AFGFR2FGFR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | FPR2 258/4885KDM1A 887/4885FGFR2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.